anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This two-arm pilot study will be used to estimate the effect size in weight loss of supplementing the WW (formerly Weight Watchers) online program with gamified inhibitory control training (PolyRules!) among adults with overweight or obesity. Participants ages 18 and older (n=30) will be randomly assigned to one of two study arms: (1) WW (formerly Weight Watchers) only or (2) WW + Gamified inhibitory control training (PolyRules!). All participants will complete demographic, medical history questionnaires and cognitive assessment battery at baseline/enrollment and after completing the 3-month intervention protocol. All interactions with PolyRules! and WW will be passively recorded to monitor the frequency of interaction with WW and PolyRules!.
The invention relates to an ointment for treating beriberi, belonging to an ointment for external use in the traditional Chinese medicine. Fish oil, borneol, albolene and the like are mixed and prepared into an ointment type according to a certain ratio. The ointment provided by the invention has the effects of diminishing inflammation, relieving itching, clearing heat, detoxifying and sterilizing, and takes effect rapidly on the treatment of the beriberi and is free from toxic and side effects. A patient applies the ointment on affected parts of the skin twice a day conveniently when the ointment is utilized, and the general beriberi can stop itching after the ointment is applied once. The ointment for external use provided by the invention is simple in technology, low in cost, and can reduce the financial burden of the patients. In addition, the ointment for treating beriberi provided by the invention is low in investment, takes effect quickly, and produces great economic benefits and social benefits.
Novel cancer cell inhibitors have been isolated from the venoms of poisonous snakes Crotalus atrox and Naja n. kaouthia; they are called Atroporin and Kaotree, respectively. The cancer cell inhibitors Atroporin and Kaotree are characterized as potent anti cancer agents. Atroporin and Kaotree, individually, or combined together selectively kill various types of cancer cells in concentrations as low as 0.5  mu g/ml. Atroporin and Kaotree are characterized as stable protein components of venoms consisting of peptides whose molecular weights are approximately 35,000 and 6,000 daltons, revealed by gel electrophoresis. The partial sequence of Atroporin for its first fifteen N-terminal amino acids is:SEQ ID: 1 =[Val, Ile]-[Val, Ile]-Gly-Gly-Asp-Glu-(Cys)-Asn-Ile-Asn- Glu-His-Arg-Ser-Leuand, similarly for Kaotree:SEQ ID: 2=Met-Glu-Cys-Tyr-Arg-Met-Ser-Asn-Ile-Val- Thr-Cys-Gln-Pro-Trp.Neither of these sequences appear in standard data bases including all known proteins, therefore they are novel proteins. Atroporin and Kaotree have cytolytic, i.e. killing effect, on various types of cancer cells and are claimed as versatile anti cancer agents. Furthermore, Atroporin and Kaotree are claimed as therapeutic agents for a wide range of cancers such as: breast, colon, liver, lung pharynx ovary etc. It is also an object of this invention to provide two different embodiments such as Atroporin and Kaotree, or the combination of both, as compositions for the treatment of various types of cancers as a biotherapy.
INTRODUCTION: Patients suffering from severe chronic pain often have problems finding an appropriate combination of painkillers. We retrospectively evaluated the effectiveness and safety of pulsed radiofrequency ablation (pRFA) of the genicular nerves in 96 patients with knee osteoarthritis (KO). We hypothesized that age, sex, and body mass index (BMI) may influence the quality of the pRFA treatment.
MATERIAL AND METHODS: A diagnostic blockade with total volume of 9 ml of 1% lidocaine (WZF, Poland) combined with 4 mg of dexamethasone with subsequent pRFA with a radio frequency of 300-500 kHz under ultrasound guidance was used during the procedure. The study participants were assessed during regular monthly visits until 12 months.
RESULTS: The nerves' ultrasound identification was successful in 90.62% of the cases. According to the numeric rating scale (NRS), pain was reduced by 50% or more in 64.06% of the cases. The average pain relief period lasted just over 7 and a half months. There were no pRFA-related complications or side effects of the drugs used.
CONCLUSIONS: pRFA seems to be safe and effective for the treatment of chronic pain in KO. The outcome of the treatment may be related to the patient's age (block duration increased with patient age) and sex (in women, the therapeutic effect was more effectively prolonged) in our study group. There was also higher effectiveness of pRFA in high-BMI patients, which was close to statistical significance ( P = 0.053).
The invention belongs to the field of biomedicine, and relates to a preparation method and application of a liver-targeted vesicle. The invention provides a preparation method of vesicles, which comprises the step of treating induced vesicles by using an ultrasonic method. The inventor researches and finds that the expression quantity of GalNAc and Gal on the surface of the inducing vesicle is obviously increased after the inducing vesicle is subjected to ultrasonic treatment. Thus, a method for improving the liver targeting of the inducing vesicle is obtained. The inductive vesicle can be used as a medicine to achieve the effect of treating diseases. Meanwhile, the inventor finds that the induced vesicles and the nanoparticles which are subjected to ultrasonic treatment and co-incubation can obtain the engineered vesicles coated with the nanoparticles. The induced vesicle can be used as a drug carrier to wrap specific drugs for treating liver diseases, and the drugs for treating specific diseases can be wrapped while the disease treatment effect of IEVs is exerted, so that the focus can be reached in a targeted manner, the drug effect of combined treatment is exerted, and the specific practical significance is good.
This project is the first step in testing a new intervention programme, called BRIDGE (Brief, Intensive Assessment and Integrated Formulation), for young people early in the course of Borderline Personality Disorder (BPD). The BRIDGE Project will help us find out whether we can do a much bigger study in the future that will tell us whether BRIDGE works well. BPD is characterised by long standing difficulty in managing emotional responses, personal relationships, impulse control and self-image. Research shows that individuals with BPD may experience discrimination and resulting stigmatisation by both the public and health care professionals. Many adolescents and young people with complex needs and high suicide risk are left under-diagnosed and untreated. As a result, young people with BPD are frequently not in education or training and experience challenging relationships with friends and families. The overall aim of the study is to assess the possibility of providing a treatment programme for young people with BPD symptoms in the general population, who may or may not be accessing any mental health services. First, we need to see whether young people are comfortable with random allocation to BRIDGE (AND service as usual) or Service-as-usual (ALONE) (a bit like tossing a coin). Second, we need to find out whether enough young people want to be involved. Third, whether we can find out the information we need about them and can follow up enough young people later. The proposed study will try to find these things out, so that we can design a future, bigger, study to find out whether BRIDGE is good value for young people with BPD.
PURPOSE:The titled agent, containing abietic acid as an active constituent, and useful for treating allergic diseases, e.g. serotinus dermatitis, etc. CONSTITUTION:An antiallergic agent containing abietic acid expressed by the formula as an active constituent. The abietic acid is easily obtained from pine resin by leaching the pine resin with an alcohol, and distilling the resultant leachate with superheated steam or under reduced pressure. The abietic acid is found to have the antiallergic action from the effect on the serotinus dermatitis in mice and inhibitory action on passive cutaneous anaphylaxis (PCA) reactions in guinea pigs. The abietic acid is assumed to be effective for treating allergies of adults in 300-400mg dose a time administered 2-3 times a day.
The control group receives usual cardiac rehabilitation, which consists of 8-wk supervised outpatient exercise with 2 weekly sessions of 1,5 hr with high-intensity interval and resistance training. The program was complemented with a weekly session of group-based patient education for 1,5 hr on heart disease, psychological issues and diet counseling. In addition, patients had one or more individual sessions with a cardiologist and a nurse respectively. .
FIELD: agriculture; veterinary medicine. SUBSTANCE: drug is emulsion based on extracted active substances of plant origin. The mix of herbs for extraction includes calendula flowers, ripple-seed plantain, common origanum, common St. Johnswort, mother-of-thyme, little-leaf linden, common motherwort, greater celandine, yarrow, birch tree leaves, coriander seeds, cowberry leaves, bay willow flowers, currant leaves, wild camomile, and peppermint (equal parts). Doses of 5-7 ml of slightly heated medicine are administered twice a day after milking by means of a syringe and udder catheter into the affected udder quarter. EFFECT: effective prophylaxis and treatment of mastitis. 1 tbl
The objective of this randomized pilot study is to investigate the safety and potential efficacy of a CsA implant in participants with lacrimal gland involvement and aqueous tear deficiency related to GVHD. Safety will be evaluated in terms of adverse events related to the implant. Efficacy will be evaluated by changes in Schirmer tear test (with anesthesia). Secondary efficacy evaluation will include changes in corneal and conjunctival staining grades, best-corrected visual acuity (BCVA), the Ocular Surface Diseases Index (OSDI), changes in conjunctival GVHD grades, tear break-up time and meibomian gland dysfunction.

Participants with active systemic GVHD with aqueous tear deficiency associated with lacrimal gland dysfunction following allogeneic hematopoietic SCT who are nine years of age or older are eligible for inclusion in this pilot study. The study will involve surgical placement of the CsA implant into the subconjunctival space adjacent to the lacrimal gland of one eye in each participant. Participants older than 12 years of age will be randomized to receive one of two implant release rates. However, all participants under age 12 will not be randomized and will only be eligible to receive the smaller, lower dose implant. On each anniversary study visit a participant will be given the opportunity to retain the implant on an annual basis. This will be based upon the determination of clinical success (defined in the Study Design section below) combined with a participant's report of symptom improvement. The Implant will be removed if the Investigator believes the implant is harmful or if the participant requests the implant to be removed.
BACKGROUND: The correlation between the standardized resource use ratio (SRUR) and standardized hospital mortality ratio (SMR) for neurosurgical emergencies is not known. We studied SRUR and SMR and the factors affecting these in patients with traumatic brain injury (TBI), nontraumatic intracerebral hemorrhage (ICH), and subarachnoid hemorrhage (SAH).
METHODS: We extracted data of patients treated in six university hospitals in three countries (2015-2017). Resource use was measured as SRUR based on purchasing power parity-adjusted direct costs and either intensive care unit (ICU) length of stay (costSRURlength of stay) or daily Therapeutic Intervention Scoring System scores (costSRURTherapeutic Intervention Scoring System). Five a priori defined variables reflecting differences in structure and organization between the ICUs were used as explanatory variables in bivariable models, separately for the included neurosurgical diseases.
RESULTS: Out of 28,363 emergency patients treated in six ICUs, 6,162 patients (22%) were admitted with a neurosurgical emergency (41% nontraumatic ICH, 23% SAH, 13% multitrauma TBI, and 23% isolated TBI). The mean costs for neurosurgical admissions were higher than for nonneurosurgical admissions, and the neurosurgical admissions corresponded to 23.6-26.0% of all direct costs related to ICU emergency admissions. A higher physician-to-bed ratio was associated with lower SMRs in the nonneurosurgical admissions but not in the neurosurgical admissions. In patients with nontraumatic ICH, lower costSRURs were associated with higher SMRs. In the bivariable models, independent organization of an ICU was associated with lower costSRURs in patients with nontraumatic ICH and isolated/multitrauma TBI but with higher SMRs in patients with nontraumatic ICH. A higher physician-to-bed ratio was associated with higher costSRURs for patients with SAH. Larger units had higher SMRs for patients with nontraumatic ICH and isolated TBI. None of the ICU-related factors were associated with costSRURs in nonneurosurgical emergency admissions.
CONCLUSIONS: Neurosurgical emergencies constitute a major proportion of all emergency ICU admissions. A lower SRUR was associated with higher SMR in patients with nontraumatic ICH but not for the other diagnoses. Different organizational and structural factors seemed to affect resource use for the neurosurgical patients compared with nonneurosurgical patients. This emphasizes the importance of case-mix adjustment when benchmarking resource use and outcomes.
PURPOSE:To provide a composition giving highly excellent contrast effect, also high in safety, characterized by using a trace amount of manganese as the ingredient having the negative effect in taking relaxation time:T2- emphasizing images in the MRI image taking for digestive tract diagnosis. CONSTITUTION:The objective composition, which is used in the MRI image taking for digestive tract diagnosis, containing (A) manganese as contrast medium and, optionally, (B) a food/beverage (esp. a manganese compound, manganese-contg. food/beverage). The manganese concentration in its practical use is pref. 5-80 (pref. 5-50mug/ml in the solution. At such concentrations, the manganese extends the relaxation time:T2 of the water in the body; as a result, having such contrast effect (negative effect) as to manifest a MRI image gray to black. For the manganese, a manganese compound other than food additives can be used (e.g. manganese chloride). Also, manganese-rich food ingredient(s) such as blueberry fruit juice or powdered tea can be used. Thus, the objective composition of food type playing a role as an ideal contrast medium can be obtained.
PURPOSE: Ursodesoxycholic acid-synthetic hydrotalcite-eudragit nanohybrid, a pharmaceutical composition containing the same, and a method for preparing the same are provided to block the distinct bitter taste of ursodesoxycholic acid by inserting the ursodesoxycholic acid into the interlayer of synthetic hydrotalcite and implementing an eudragit coating process. CONSTITUTION: MgCl_2·6H_2O and AlCl_3·9H_2O are dissolved in carbonate ion-eliminated third distilled water to obtain a mixture. Ursodesoxycholic acid is mixed with the mixture. Ursodesoxycholic acid-synthetic hydrotalcite composite is obtained based on NaOH aqueous solution. Stirring, vacuum filtrating, and cleaning processes are implemented with respect to the composite. Non-reacted salt is eliminated from the composite. Ursodesoxycholic Acid is inserted into the interlayer of synthetic hydrotalcite.
OBJECTIVES: Despite the individualized starting dose for maintenance therapy in ovarian cancer, the niraparib dose reduction rate remains high. The aim of this study was to evaluate the impact of niraparib dose reduction on progression-free survival in newly diagnosed primary advanced ovarian cancer and recurrent ovarian cancer patients. We also aimed to compare the reduction rates and the safety of niraparib on primary and relapse groups, and identify which factors may predict dose reduction.
METHODS: Patients with primary or recurrent ovarian cancer in maintenance who received niraparib between 2019 and 2022 were retrospectively evaluated. Niraparib dosing was based on individualized starting dose of 300 or 200 mg/day. The impact of niraparib dose reductions was focused on patients treated with 200 or 100 mg in both groups. Reduction rates, adverse events and predictive factors of reduction were assessed in each study group. The primary endpoint was progression-free survival in primary and relapse groups; the secondary endpoints were the reduction rates, the safety and tolerability of niraparib in both groups.
RESULTS: Of 215 patients identified, 124 (57.7%) primary and 91 (42.3%) recurrent ovarian cancer patients were included. The majority of patients started niraparib at 200 mg/day (92.7% primary and 80.2% relapse group); dose reductions from 300 or 200 mg/day to 200 or 100 mg/day occurred more frequently within cycles 1-3 (67% primary and 45% relapse group, p=0.001). Grade≥3 adverse events were lower in the relapse group (54.8% primary and 35.1% relapse, p=0.001). In both groups, dose modifications over the treatment did not significantly impair median progression-free survival. Univariate and multivariate analysis demonstrated that weight and platinum-doublets were possible risk factors for dose reduction.
CONCLUSIONS: Niraparib dose reduction occurs in almost half of patients within cycles 1-3, although it is significantly more common in the first-line setting. Survival outcomes seem not to be impaired by dose reduction.
The invention relates to a polypeptide and application thereof in promoting bone repair, belonging to the technical field of biological medicines. The amino acid sequence of the polypeptide provided by the invention is shown as SEQ ID NO. 1. The invention also discloses application of the polypeptide KS32 in bone injury and/or bone repair. Furthermore, the invention also discloses a polypeptide scaffold for bone repair. The polypeptide KS32 can attract and collect cells into a bone repair material, has the effect of accelerating the repair and regeneration of bone defects, and can be used as a functional factor of bone tissue engineering.
A combined approach for maximal support and reinforcement. The intervention included 8 hours of online diabetes education, 30 minute 1:1 virtual education and counseling with a diabetes educator, access to the app with online diabetes support tools and ability to message a diabetes specialist for support, and 3 and 6-month follow-ups.
Approximately 50% of the administered dose of sulindac is excreted in the urine with the conjugated sulfone metabolite accounting for the major portion. Less than 1% of the administered dose of sulindac appears in the urine as the sulfide metabolite. Approximately 25% is found in the feces, primarily as the sulfone and sulfide metabolites.

The mean effective half life (T1/2) is 7.8 and 16.4 hours, respectively, for sulindac and its active sulfide metabolite.

Because sulindac is excreted in the urine primarily as biologically inactive forms, it may possibly affect renal function to a lesser extent than other non-steroidal anti-inflammatory drugs; however, renal adverse experiences have been reported with sulindac (see ADVERSE REACTIONS).

In a study of patients with chronic glomerular disease treated with therapeutic doses of sulindac, no effect was demonstrated on renal blood flow, glomerular filtration rate, or urinary excretion of prostaglandin E2 and the primary metabolite of prostacyclin, 6-keto-PGF1α. However, in other studies in healthy volunteers and patients with liver disease, sulindac was found to blunt the renal responses to intravenous furosemide, i.e., the diuresis, natriuresis, increments in plasma renin activity and urinary excretion of prostaglandins. These observations may represent a differentiation of the effects of sulindac on renal functions based on differences in pathogenesis of the renal prostaglandin dependence associated with differing dose-response relationships of different NSAIDs to the various renal functions influenced by prostaglandins (see PRECAUTIONS).

In healthy men, the average fecal blood loss, measured over a two-week period during administration of 400 mg per day of sulindac, was similar to that for placebo, and was statistically significantly less than that resulting from 4800 mg per day of aspirin.
BACKGROUND: Preoperative estimation of the volume of the left atrium (LA) and epicardial adipose tissue (EAT) on computed tomography (CT) images is associated with an increased risk of atrial fibrillation (AF) recurrence. We aimed to design a deep learning-based workflow to provide reliable automatic segmentation of the atria, pericardium, and EAT for future applications in the management of AF.
METHODS: This study enrolled 157 patients with AF who underwent first-time catheter ablation between January 2015 and December 2017 at Taipei Veterans General Hospital. Three-dimensional (3D) U-Net models of the LA, right atrium (RA), and pericardium were used to develop a pipeline for total, LA-EAT, and RA-EAT automatic segmentation. We defined fat within the pericardium as tissue with attenuation between -190 and -30 HU and quantified the total EAT. Regions between the dilated endocardial boundaries and endocardial walls of the LA or RA within the pericardium were used to detect voxels attributed to fat, thus estimating LA-EAT and RA-EAT.
RESULTS: The LA, RA, and pericardium segmentation models achieved Dice coefficients of 0.960 ± 0.010, 0.945 ± 0.013, and 0.967 ± 0.006, respectively. The 3D segmentation models correlated well with the ground truth for the LA, RA, and pericardium ( r = 0.99 and p < 0.001 for all). The Dice coefficients of our proposed method for EAT, LA-EAT, and RA-EAT were 0.870 ± 0.027, 0.846 ± 0.057, and 0.841 ± 0.071, respectively.
CONCLUSION: Our proposed workflow for automatic LA, RA, and EAT segmentation using 3D U-Nets on CT images is reliable in patients with AF.
Zometa will be administered intravenously every 28 days beginning on day 0. Cyclophosphamide will be administered daily without interruption (unless toxicity supervenes) beginning day 0. Each course of therapy will be 28 days. On day 0 of each cycle, cyclophosphamide should be given first, followed by Zometa with a separation between the two drugs of at least one hour. All patients are required to take calcium and Vitamin D supplementation for the duration of study participation.
In animals, diazepam appears to act on parts of the limbic system, the thalamus and hypothalamus, and induces calming effects. Diazepam, unlike chlorpromazine and reserpine, has no demonstrable peripheral autonomic blocking action, nor does it produce extrapyramidal side effects; however, animals treated with diazepam do have a transient ataxia at higher doses. Diazepam was found to have transient cardiovascular depressor effects in dogs. Long-term experiments in rats revealed no disturbances of endocrine function. Injections into animals have produced localized irritation of tissue surrounding injection sites and some thickening of veins after intravenous use.

Population PK analysis in 87 pediatric patients 0.4 – 17.8 years of age with status epilepticus showed that, after initial dosing, the median plasma half-life was 0.5 hours and the median terminal elimination plasma half-life was 18 to 25 hours.